GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » 3SBio Inc (OTCPK:TRSBF) » Definitions » Debt-to-Revenue

3SBio (TRSBF) Debt-to-Revenue : 0.60 (As of Dec. 2023)


View and export this data going back to 2018. Start your Free Trial

What is 3SBio Debt-to-Revenue?

Debt-to-Revenue measures a company's ability to pay off its debt.

3SBio's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $297 Mil. 3SBio's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2023 was $380 Mil. 3SBio's annualized Revenue for the quarter that ended in Dec. 2023 was $1,129 Mil. 3SBio's annualized Debt-to-Revenue for the quarter that ended in Dec. 2023 was 0.60.


3SBio Debt-to-Revenue Historical Data

The historical data trend for 3SBio's Debt-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

3SBio Debt-to-Revenue Chart

3SBio Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Debt-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.53 0.52 0.41 0.66 0.62

3SBio Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Debt-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.40 0.62 0.60 0.66 0.60

Competitive Comparison of 3SBio's Debt-to-Revenue

For the Biotechnology subindustry, 3SBio's Debt-to-Revenue, along with its competitors' market caps and Debt-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


3SBio's Debt-to-Revenue Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, 3SBio's Debt-to-Revenue distribution charts can be found below:

* The bar in red indicates where 3SBio's Debt-to-Revenue falls into.



3SBio Debt-to-Revenue Calculation

Debt-to-Revenue measures a company's ability to pay off its debt.

3SBio's Debt-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(297.098 + 380.452) / 1094.639
=0.62

3SBio's annualized Debt-to-Revenue for the quarter that ended in Dec. 2023 is calculated as

Debt-to-Revenue=Total Debt / Revenue
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Revenue
=(297.098 + 380.452) / 1129.41
=0.60

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-Revenue, the Revenue of the last fiscal year is used. In calculating the annualized quarterly data, the Revenue data used here is two times the quarterly (Dec. 2023) Revenue data.


3SBio Debt-to-Revenue Related Terms

Thank you for viewing the detailed overview of 3SBio's Debt-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


3SBio (TRSBF) Business Description

Traded in Other Exchanges
Address
No. 3 A1, Road 10, Shenyang Economy and Technology Development Zone, Shenyang, CHN, 110027
3SBio Inc, or 3SBio, is one of the largest and most established biotech drugmakers in China. In 2021, it reported revenue of CNY 6.3 billion. Approximately 90% of its revenue is derived from four core drugs: TPIAO (rhTPO), Yisaipu (biosimilar of etanercept, a TNF-alpha inhibitor), rhEPO, and Mandi (minoxidil). With the exception of minoxidil, an over-the-counter drug, the others are all older generation biologics. Most of the pipeline candidates are "me-too" drugs and in general are still at an early stage.

3SBio (TRSBF) Headlines

No Headlines